Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of Tobemstomig in patients with advanced solid tumors
jRCT2031230196Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of tobemstomig in Nonhematologic neoplasms (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicity (DLT), Safety and 1 more. Started Aug 2023; status: completed.
02
Drugs
tobemstomig
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031230196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230196.